Therapy for Heart Failure: The Leipzig Approach

J. Gummert; M. Barten; A. Rahmel; S. Doll; R. Krakor; J. Garbade; R. Autschbach

doi:10.1055/s-0037-1601348

The Thoracic and Cardiovascular Surgeon, Table of Contents

Thorac Cardiovasc Surg 2017; 65(S 03): S205-S208
DOI: 10.1055/s-0037-1601348

Tribute

Georg Thieme Verlag KG Stuttgart · New York

Therapy for Heart Failure: The Leipzig Approach

Authors

J. Gummert

¹Direktor der Klinik für Thorax- und Kardiovaskularchirurgie Herz- und Diabeteszentrum Nordrhein Westfalen Bad Oeynhausen, Germany
M. Barten

²Universitäres Herzzentrum Hamburg GmbH (UHZ) Klinik und Poliklinik für Herz-und Gefäßchirurgie, Hamburg, Germany
A. Rahmel

³Deutsche Stiftung Organtransplantation, Germany
S. Doll

⁴Praxis für Kardiologie, Leinfelden-Echterdingen, Germany
R. Krakor

⁵Klinikum Dortmund gGmbH, Dortmund. Germany
J. Garbade

⁶Herzzentrum Leipzig – Universitätsklinik, Leipzig, Germany
R. Autschbach

⁷Klinik für Herzchirurgie – Universitätsklinik Aachen, Aachen, Germany

Abstract

All articles of this category

Full Text

References

References
1 Schütz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341 (8842): 436
2 Gummert JF, Rahmel A, Bucerius J , et al. Mitral valve repair in patients with end stage cardiomyopathy: who benefits?. Eur J Cardiothorac Surg 2003; 23 (6) 1017-1022 , discussion 1022
3 Doll N, Opfermann UT, Rastan AJ , et al. Facilitated minimally invasive left ventricular epicardial lead placement. Ann Thorac Surg 2005; 79 (3) 1023-1025 , discussion 1025
4 Gummert JF, Doll N, Rahmel A, Richter M, Bossert T, Mohr FW. Surgical strategies for the treatment of heart failure [in German]. Z Arztl Fortbild Qualitatssich 2003; 97 (2) 121-126
5 Oz MC, Konertz WF, Kleber FX , et al. Global surgical experience with the Acorn cardiac support device. J Thorac Cardiovasc Surg 2003; 126 (4) 983-991
6 Gummert JF, Schneider J, Bossert T, Krakor R, Mohr FW. The acorn cardiac support device (CD) randomized trial: Perioperative results and early follow-up in 26 patients—A single center experience. J Heart Lung Transplant 2002; 21 (1) 126-127
7 Gummert JF, Rahmel A, Bossert T, Mohr FW. Socks for the dilated heart. Does passive cardiomyoplasty have a role in long-term care for heart failure patients?. Z Kardiol 2004; 93 (11) 849-854
8 Bossert T, Bittner HB, Richter M , et al. Successful management of two heart transplant recipients with mycobacterial pulmonary infections. Ann Thorac Surg 2005; 80 (2) 719-721
9 Gummert JF, Falk V, Walther T , et al. Tonsillar carcinoma in the early postoperative course following heart transplantation. Thorac Cardiovasc Surg 1995; 43 (6) 355-357
10 Aupperle H, Garbade J, Ullmann C , et al. Ultrastructural findings in porcine hearts after extracorporeal long-term preservation with a modified Langendorff perfusion system. J Vet Med A Physiol Pathol Clin Med 2007; 54 (5) 230-237
11 Aupperle H, Garbade J, Ullmann C , et al. Comparing the ultrastructural effects of two different cardiac preparation- and perfusion-techniques in a porcine model of extracorporal long-term preservation. Eur J Cardiothorac Surg 2007; 31 (2) 214-221
12 Garbade J, Krautz C, Aupperle H , et al. Functional, metabolic, and morphological aspects of continuous, normothermic heart preservation: effects of different preparation and perfusion techniques. Tissue Eng Part C Methods 2009; 15 (2) 275-283
13 Gummert JF, Schütz E, Oellerich M, Mohr FW, Dalichau H. Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine. Artif Organs 1995; 19 (9) 918-920
14 Schütz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27 (1) 1298-1300
15 Schütz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996; 34 (3) 199-205
16 Schütz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?. Ther Drug Monit 1996; 18 (3) 228-233
17 Richter MH, Richter H, Barten M , et al. Angiotensin II type 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study. Transplant Proc 2002; 34 (5) 1484-1485
18 Richter MH, Richter H, Barten M , et al. Cyclosporin A does not enhance the development of transplant vasculopathy: experimental study in a rat cardiac transplant model. Transplant Proc 2002; 34 (5) 1479-1480
19 Barten MJ, Dhein S, Chang H , et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J Immunol Methods 2003; 283 (1-2): 99-114
20 Barten MJ, Streit F, Boeger M , et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004; 77 (8) 1154-1162
21 Barten MJ, Rahmel A, Garbade J , et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. Transplant Proc 2005; 37 (10) 4532-4534
22 Barten MJ, Rahmel A, Garbade J , et al. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. Transplant Proc 2005; 37 (2) 1360-1361
23 Barten MJ, Shipkova M, Bartsch P , et al. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. Ther Drug Monit 2005; 27 (2) 123-131
24 Barten MJ, Garbade J, Bittner HB , et al. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation. Int Immunopharmacol 2006; 6 (13-14): 2011-2017
25 Barten MJ, Rahmel A, Bocsi J , et al. Cytokine analysis to predict immunosuppression. Cytometry A 2006; 69 (3) 155-157
26 Boldt A, Barten MJ, Sagner A , et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. Transplantation 2006; 82 (3) 422-427
27 Boldt A, Barten MJ, Weiss C, Sagner A, Mohr FW, Gummert JF. Novel apoptosis assay to analyze immunosuppression. Cytometry A 2006; 69 (3) 158-160
28 Barten MJ, Rahmel A, Boldt A , et al. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function. Comput Biol Med 2007; 37 (10) 1367-1373
29 Barten MJ, Tarnok A, Garbade J , et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007; 40 (1) 50-63
30 Gummert JF, Barten MJ, Bartsch P , et al. Pharmacodynamic (PD) measurements of the immunosuppressive effects of the combination of cyclosporine (CY) and mycophenolate mofetil (MMF): correlation between drug dose and lymphocyte function. J Heart Lung Transplant 2001; 20 (2) 163
31 Barten MJ, Rahmel A, Boeger M , et al. Pharmacodynamics of sirolimus and cyclosporine combination therapy. Transplant Proc 2002; 34 (7) 2878
32 Barten MJ, Rahmel A, Chang H , et al. Assessment of immunosuppression by lymphocyte functions in human blood. Transplant Proc 2002; 34 (7) 2876-2877
33 Barten MJ, Rahmel A, Richter M , et al. Pharmacodynamics of the immunosuppressive effects of the combination of tacrolimus with mycophenolate mofetil. Transplant Proc 2002; 34 (6) 2372-2373